$73k for the quarter. Q1 last year was $75k, so they have been so obsessed with shareholder dilution and TGA that they forgot to try and sell anything.
The company will not be built off one product. What if the goop is a relative flop and gets little market penetration. At least the directors will get paid
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add SKN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.357M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $2.921K | 730.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 149776 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 1792258 | 5 |
View Market Depth
| Last trade - 10.18am 23/08/2024 (20 minute delay) ? |
| SKN (ASX) Chart |